Alkermes Stock Hits New 52-Week High (ALKS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Alkermes (Nasdaq: ALKS) hit a new 52-week high Monday as it is currently trading at $32.57, above its previous 52-week high of $32.33 with 185,362 shares traded as of 9:46 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Alkermes has a market cap of $4.04 billion and is part of the health care sector and drugs industry. Shares are up 30.8% year to date as of the close of trading on Friday.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Alkermes as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Alkermes Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round